Equity Research Database

Institutional Investment Pitches

Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.

Home Letters Funds Account

Longleaf Partners Global Fund's investment thesis on Regeneron Pharma ($REGN) — Q2 2026 | Buyside Digest

All Pitches

View Letter Analysis

$REGNNASDAQRegeneron Pharma

NEUTRAL

Longleaf Partners Global Fund—REGN

Fund Letter

Q2 2026

Published July 11, 2026

View Fund Profile

$768.58USD

-7.1% vs last month

$676.69Pitched

+13.6% since pitch

Market Cap$78.8B

P/E (TTM)N/A

52-Wk RangeN/A

Div. YieldN/A

Technical Chart

From the Fund Letter

Southeastern's Global Fund returned 5.90% in Q2 2026, underperforming the MSCI World's 13.76% return as over 100% of relative underperformance came from underweight positions in overvalued Information Technology and AI-related stocks. The manager views...

— Ross Glotzbach

BSD Research Exclusive

Unlock Full Institutional Investment Theses

Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($55/mo) and Pro subscribers.

6,000+ Institutional Pitches

Proprietary AI Analysis

100 Letter Unlocks/Cycle

SUBSCRIBE TO BSD RESEARCH ($55/MO)Compare All Plans

Already a Research or Pro subscriber? Sign In

◆ Keep Reading

What other investors think about $REGN, and what else Longleaf Partners Global Fund is buying.

Other pitches on $REGN

Other investors who've written on Regeneron Pharma

No other institutional pitches found for this ticker yet.

View all $REGN pitches →